Drug patents …
… from Kazakhstan to Kalamazoo
Manage your formulary budget
Deep knowledge on
small-molecule drugs and
the 110,000 global patents
Proactively manage your pharmacy inventory
Anticipate generic drug launch
Find generic entry opportunities
|Title:||Liposomes with enhanced circulation time|
|Abstract:||A liposome composition which contains between 1-20 mole percent of an amphipathic lipid derivatized with a polyalkylether, as exemplified by phosphatidylethanolamine derivatized with polyethyleneglycol. The derivatized lipid enchances the circulation time of the liposomes severalfold, and this enhancement is achieved with either fluid or membrane-rigidifying liposome components. Also disclosed are methods for delivering a drug for slow release from the bloodstream, and for targeting a selected tissue or cells with liposomes, via the bloodstream.|
|Inventor(s):||Woodle; Martin C. (Menlo Park, CA), Martin; Francis J. (San Francisco, CA), Yau-Young; Annie (Los Altos, CA), Redemann; Carl T. (Walnut Creek, CA)|
|Assignee:||Liposome Technology, Inc. (Menlo Park, CA)|
Patent Claim Types:|
see list of patent claims
|Composition; Dosage form; Delivery; Compound; Use;|
|Country||Document Number||Estimated Expiration||Supplementary Protection Certificate||SPC Country||SPC Expiration|
| This preview shows a limited data set|
Subscribe for full access, or try a Trial
The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.
Export unavailable in trial.
Subscribe for complete access.